Why does perimenopause make a GLP-1 work more slowly?

# Why does perimenopause make a GLP-1 work more slowly?

Perimenopause changes the metabolic ground you are standing on, and steady effort can start producing less than it used to. If a weight medication feels like it is working slower than you hoped, the more honest explanation is often not the medicine but the terrain it is working against. This piece walks through what actually shifts in the menopause transition, and it is careful to say where the science is solid and where a direct perimenopause comparison is still thin.

Key takeaways

Dr. Linda's take

A patient will sit down and say some version of the same thing. I am doing everything I did before, the medicine is in me, and the scale is barely moving. She wants to know what she is doing wrong. Usually the answer is nothing.

Here is the distinction I want to draw clearly, because it is where the honesty lives. There is very little head-to-head research that directly measures these medicines working "more slowly" in perimenopausal women than in anyone else. What we do have is a well-described picture of what perimenopause does to metabolism, and that picture explains why the same medicine can produce a slower-feeling result. The drug is doing its job against a metabolic baseline that has quietly shifted underneath you. Those are two different claims, and I will not blur them into a promise the data cannot back.

If you want a starting point for whether any of this fits your situation, our eligibility quiz is one place to begin. It is general education, not a plan for you specifically.

What changes in your metabolism during perimenopause?

Perimenopause is not just lower hormones. It is a reshuffling of how your body stores fat, spends energy, and handles sugar.

Start with the hormone itself. During the menopause transition, a decline in circulating estradiol and progesterone reaches well beyond reproductive health and significantly influences metabolic homeostasis. That single shift ripples outward into fat, muscle, and insulin all at once.

Fat moves first, and it moves inward. Perimenopause is marked by an expansion of visceral adipose tissue, the deep fat packed around the abdominal organs, alongside a reduction in the subcutaneous fat at the hips and thighs, even when weight gain is minimal-to-modest. In the same window, menopause itself is associated with an increase in total body fat and visceral fat, not only a change in where it sits.

This is not a vanity point. That redistribution toward visceral fat is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events. The middle changing in your forties is a biology story, and the biology is pointing at the fat depot that carries the most metabolic risk.

Sugar handling shifts too. In premenopausal women, estrogen helps protect the insulin-producing cells of the pancreas, and that support diminishes during the menopause transition. As that protection fades, insulin resistance tends to rise, which makes it harder for the body to move fuel out of the blood and into cells efficiently.

Does muscle loss slow weight loss?

This is the part that quietly sets your metabolic floor, and perimenopause works against it.

Muscle is metabolically expensive tissue, so how much of it you carry helps set how many calories you burn at rest, and this stage tends to chip away at it.

Less muscle means a lower engine idle. A lower lean mass in postmenopausal women is associated with a lower resting metabolic rate. And the resting rate really does fall: postmenopausal women have a significantly lower resting metabolic rate than premenopausal women. Layer on the whole-day picture and across the menopause transition twenty-four-hour energy expenditure drops by roughly 200 kilocalories a day, a magnitude large enough to cause meaningful weight gain by itself.

Put those together and you have the mechanistic reason weight loss can feel slower. Fewer calories burned at rest, rising insulin resistance, and fat parked in the most stubborn depot all mean the same food and the same medicine push against more resistance than they would have a decade earlier. Because rapid weight loss can itself cost muscle, protecting it becomes even more important in this season, which we cover in our companion on muscle loss in perimenopause.

Does a GLP-1 still work during perimenopause?

Yes. The mechanism above explains a slower feel, not a broken medicine.

These medicines remain genuinely powerful. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% on placebo. That is a large, well-replicated effect. The honest asterisk is who was studied. That trial enrolled general adults with obesity, not women selected for the menopause transition, so I am reporting a robust general effect and telling you plainly it was not isolated to perimenopausal women.

So the realistic expectation is this. The medicine still lowers appetite and drives fat loss, but it is doing so while your resting metabolism, muscle, and insulin sensitivity have shifted in ways that blunt the pace. A slower curve is not the same as a failing one. If your belly is the part changing most, our companion on perimenopause belly fat covers that ground.

What can you ask your clinician?

You do not need to accept "just be patient" as the whole answer. Reasonable questions include what your realistic pace looks like given the metabolic changes of this stage, whether strength training and protein should be built in from the start to protect muscle, and whether anything else in your picture is worth checking. Whether this medication is a fit for you at all is its own conversation, and we lay out the groundwork in our companion on starting this class of medicine during perimenopause. A licensed clinician who knows your history is the person to weigh it with.

Frequently asked questions

Does perimenopause make a GLP-1 stop working?

No. There is no good evidence these medicines stop working in perimenopause, and their weight-loss effect is large in trials. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% on placebo. What changes is the metabolic baseline the medicine works against, not the medicine itself.

Why does weight loss feel slower in perimenopause?

Because the body burns less and stores differently. Across the menopause transition twenty-four-hour energy expenditure drops by roughly 200 kilocalories a day. With fewer calories spent at rest, the same effort produces a smaller gap.

Does losing muscle lower your metabolism?

It contributes. A lower lean mass in postmenopausal women is associated with a lower resting metabolic rate. With less of that metabolically active tissue, the body burns fewer calories at rest, which is why protecting muscle with strength work matters in this stage.

Is the belly fat in perimenopause different?

Yes. Perimenopause expands the deep visceral fat around the abdominal organs while reducing subcutaneous fat at the hips and thighs. That visceral pattern is the kind most tied to cardiovascular risk, not just appearance.

References

1. Estrogen and Metabolism: Navigating Hormonal Transitions from Perimenopause to Postmenopause (2025). PMC / National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC12431702/ (Accessed 2026-07-24).
2. Perimenopausal and menopausal visceral adipose tissue expansion and gluteofemoral fat reduction (2026). PubMed / National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/41567597/ (Accessed 2026-07-24).
3. Lovejoy JC, et al. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. PMC / National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC2748330/ (Accessed 2026-07-24).
4. Duval K, et al. (2013). Lower resting and total energy expenditure in postmenopausal compared with premenopausal women matched for abdominal obesity. PMC / National Library of Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC4153012/ (Accessed 2026-07-24).
5. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). PubMed / New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-24).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-24.*